Building on our previous research [15], further analysis of tumor progression within the training set revealed that RPN1 may act as a suppressor of prostate cancer progression (Fig. 1C), while OXSM, NDUFA11, and SLC7A11 appear to promote disease progression (Fig. 1E, F). Here, SLC7A11 is linked to prostate carcinoma.